SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01801904

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer

The purpose of this study is to assess if panitumumab is active enough to warrant comparative studies in patients with metastatic colorectal cancer that has progressed after treatment with cetuximab.

NCT01801904 Metastatic Colorectal Cancer
MeSH:Colorectal Neoplasms
HPO:Neoplasm of the large intestine

1 Interventions

Name: Panitumumab

Description: 6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
Type: Drug
Group Labels: 1

Panitumumab


Primary Outcomes

Description: progression of disease within 2 months from registration according to RECIST criteria, and death for any cause within 2 months from registration

Measure: number of patients alive and without disease progression

Time: 2 months

Secondary Outcomes

Description: Response assessed per patients at weeks 8,16,24,32,40 and every 3 months thereafter, using RECIST criteria

Measure: response rate

Time: up to 40 weeks

Measure: progression free survival

Time: 9 months

Measure: overall survival

Time: one year

Description: worst grade toxicity (according to Common Terminology Criteria for Adverse Events version 3) per patient

Measure: worst grade toxicity per patient

Time: every 2 weeks for up to 6 months

Other Outcomes

Description: exploratory analysis of tumor-tissue for biological or genomic determinants of outcome of BRAF and P13K mutation status, EGFR and PTEN expression status

Measure: gene expression on tumor tissue

Time: one year

Purpose: Treatment

Allocation: N/A

Single Group Assignment


There is one SNP

SNPs


1 P13K

exploratory analysis of tumor-tissue for biological or genomic determinants of outcome of BRAF and P13K mutation status, EGFR and PTEN expression status. --- P13K ---



HPO Nodes


HPO: